Alto Neuroscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 12, 2026, specifically the Company's 2026 Annual Meeting of Stockholders. Alto Neuroscience, Inc. is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan matters rather than financial performance.
Material Changes and Voting Results
At the Annual Meeting, approximately 83.77% of outstanding shares (26,762,809 of 31,945,516) were present or represented by proxy. The results of the four proposals were as follows:
- Proposal 1 (Election of Directors): Approved. Raymond Sanchez, M.D. received 23,133,161 votes for. Gwill York received 12,385,501 votes for, with 10,779,092 votes withheld.
- Proposal 2 (Ratification of Auditors): Approved. Deloitte & Touche LLP was ratified with 26,727,215 votes for.
- Proposal 3 (Amendment of 2024 Equity Incentive Plan): Not Approved. Stockholders rejected the amendment to treat pre-funded warrants as common stock for the "evergreen" share reserve calculation. Votes against (12,205,864) exceeded votes for (10,838,509).
- Proposal 4 (Amendment of 2024 Employee Stock Purchase Plan): Approved. Stockholders approved the similar amendment for the ESPP. Votes for (11,946,818) exceeded votes against (11,097,535).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure of the failed equity plan amendment. The rejection of Proposal 3 indicates shareholder concern regarding the dilution mechanics of the 2024 Equity Incentive Plan.
Key Facts for Investor Verification
- Verify the impact of the failed Proposal 3 on the Company's ability to issue shares under the 2024 Equity Incentive Plan and potential future dilution.
- Review the Definitive Proxy Statement (Schedule 14A) filed on March 26, 2026, for the full text of the Amended and Restated 2024 ESPP (Exhibit 10.1).
- Monitor the Board's response to the rejection of the Equity Incentive Plan amendment and any subsequent proposals to address the "evergreen" feature.
- Confirm the tenure of the newly elected Class II directors, who will serve until the 2029 annual meeting.